Ouro Medicines
Clinical trials sponsored by Ouro Medicines, explained in plain language.
-
New antibody drug targets autoimmune diseases in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called OM336 in 39 adults with active Sjogren's disease or idiopathic inflammatory myopathy who have not improved with at least two prior treatments. OM336 is an engineered antibody designed to target and potentially reduce harmful immune c…
Phase: PHASE1 • Sponsor: Ouro Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug OM336 aims to tame overactive immune system
Disease control Recruiting nowThis early-phase trial tests a new drug called OM336 in 32 adults with autoimmune cytopenias, conditions where the immune system attacks blood cells. The study focuses on safety and how the drug moves through the body, not yet on curing the disease. Participants must have tried a…
Phase: PHASE1 • Sponsor: Ouro Medicines • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC